MG217 Multi-Symptom Treatment Cream Recall Issued

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Wisconsin Pharmacal Company is recalling 690 tubes of MG217 Multi-Symptom Treatment Cream due to confirmed microbial contamination with Staphylococcus Aureus.

What this FDA recall tells you, and what most readers miss

This notice was issued by FDA on June 10, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, drugs.

What Happened

Wisconsin Pharmacal Company initiated a voluntary recall of MG217 Multi-Symptom Treatment Cream & Skin Protectant due to microbial contamination of non-sterile products, with confirmed presence of Staphylococcus Aureus. The recall is classified as Class I by the FDA and remains ongoing.

Which Products Are Affected

The affected product is MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g). A total of 690 tubes are involved, distributed nationwide in the USA and to the Bahamas. The product was manufactured by Pharmacal at 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037. Affected lot: 1024088, expiration 11/30/2026. Recall number: D-0553-2026.

What You Should Do

Consumers should check purchased products against the lot number provided. The recalling firm is Wisconsin Pharmacal Company, located at N168w22223 Main St, Jackson, WI 53037.

Why This Matters

This Class I recall involves a confirmed bacterial contaminant in a topical skin product distributed across the United States and Bahamas.

Source

FDA Recall D-0553-2026 - Wisconsin Pharmacal Company

Original source: FDA Official Notice ↗

All FDA Recalls →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this FDA recall.

What is this FDA recall about?
Wisconsin Pharmacal Company is recalling 690 tubes of MG217 Multi-Symptom Treatment Cream due to confirmed microbial contamination with Staphylococcus Aureus.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.